On February 1, 2017, the Board of Directors of WAVE Life Sciences Ltd. upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Adrian Rawcliffe to serve as a director of the Company beginning on February 1, 2017, until the Company's 2017 Annual General Meeting of Shareholders, or until his earlier resignation, retirement, removal or death. In connection with his appointment to the Board, Mr. Rawcliffe has also been appointed to serve as a member of the Audit Committee of the Board and will join existing members of the Audit Committee, Christian Henry and Koji Miura. Also on February 1, 2017, Masaharu Tanaka transitioned off the Audit Committee, and will continue to serve as a member of the Company's Board. Effective as of January 31, 2017, Takeshi Wada, Ph.D. elected to step down from the Company's Board, and will continue his engagement with WAVE as a scientific advisor. Mr. Rawcliffe currently serves as Chief Financial Officer of Adaptimmune Therapeutics plc (2015-present). The Board has determined that Mr. Rawcliffe is an independent director as defined under the listing requirements and rules of the NASDAQ Stock Market, and that Mr. Rawcliffe satisfies the independence requirements for audit committee members under Rule 10A-3 of the Exchange Act and NASDAQ Stock Market rules. In addition, the Board has determined that Mr. Rawcliffe qualifies as an audit committee financial expert, as defined in Item 401(h) of Regulation S-K promulgated by the SEC.